FDA panel supports easing restrictions on peptides, ChatGPT faces medical advice lawsuit

An FDA panel votes to ease restrictions on several peptide drugs, favored by figures like RFK Jr., despite scientific concerns about market-induced demand.

An FDA panel narrowly backs easing restrictions on unapproved peptide drugs, a move supported by RFK Jr. but questioned by scientists concerned about market-driven demand over solid science. Concurrently, ChatGPT Health launches, enabling users to connect medical records. However, a lawsuit alleges ChatGPT advised a Florida pastor to ignore serious symptoms, prompting OpenAI to caution against using AI as a sole source of medical advice.